Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.53B | 13.98B | 14.39B | 13.65B | 12.86B |
| Total Depreciation and Amortization | 4.78B | 4.74B | 4.73B | 4.64B | 4.59B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.97B | 3.48B | 2.98B | 3.77B | 3.03B |
| Change in Net Operating Assets | -2.11B | -3.06B | -1.03B | -1.27B | -1.49B |
| Cash from Operations | 19.18B | 19.14B | 21.07B | 20.79B | 19.00B |
| Capital Expenditure | -1.64B | -1.55B | -1.50B | -1.46B | -1.39B |
| Sale of Property, Plant, and Equipment | 8.00M | 13.00M | 59.00M | 59.00M | 95.00M |
| Cash Acquisitions | -14.96B | -2.92B | -2.18B | -2.15B | -3.78B |
| Divestitures | -86.00M | -88.00M | 85.00M | 156.00M | 141.00M |
| Other Investing Activities | -268.00M | -338.00M | -2.27B | -1.92B | -1.35B |
| Cash from Investing | -16.94B | -4.88B | -5.81B | -5.32B | -6.28B |
| Total Debt Issued | 17.78B | 6.67B | 1.52B | 5.05B | 7.24B |
| Total Debt Repaid | -3.25B | -4.24B | -2.48B | -2.99B | -4.53B |
| Issuance of Common Stock | 26.00M | 27.00M | 23.00M | 26.00M | 31.00M |
| Repurchase of Common Stock | -8.37B | -9.21B | -10.49B | -11.05B | -9.95B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -8.68B | -7.82B | -7.82B | -7.82B | -7.75B |
| Other Financing Activities | -239.00M | -294.00M | -298.00M | -363.00M | -173.00M |
| Cash from Financing | -2.74B | -14.87B | -19.55B | -17.14B | -15.13B |
| Foreign Exchange rate Adjustments | 319.00M | 576.00M | 226.00M | 424.00M | 8.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.00M | -24.00M | -4.05B | -1.25B | -2.40B |